Current residents

Portfolio - Current Residents - Bioimmunate


Bioimmunate Ltd. (BI), founded in 2014, is a medical device company with a unique precision blood-filtering technology for treating autoimmune diseases, designed to be used in existing filtration machines such as dialysis. The company’s platform technology is initially focused on the treatment of multiple sclerosis (MS). The company’s filters contain particles that are able to recognize, capture and remove MS-related cells from the blood, to prevent them from migrating to the brain and causing further damage to the central nervous system.


Dr. Sigalit Carmel Founder and CEO
Dr. Shimon Shteingart VP R&D
Dr. Hadar Amartely R&D Director
Mr. Omri S. Alfassy M.Sc, R&D Engineer, Manager 
Dr. Elza Snir Senior Scientist
Dr. Sandrine Benhamron Senior Scientist  

Portfolio - Current Residents - Pepticom

Pepticom logo

Pepticom Ltd. founded in 2011, is focused on the discovery of novel peptide-drug candidates. Pepticom’s key asset is a unique Artificial Intelligence platform for peptide design, based on the target's solved crystal structure. Pepticom operates in various markets, generating innovative binding peptides for diverse targets. Past successful discoveries include active molecules in metabolic diseases, Alzheimer's disease and Immunomodulators.


Dr. Immanuel Lerner CEO
Dr. Amit Michaeli Co-Founder and CTO
Dr. Maayan Elias Robicsek Business Development Officer
Dr. Shaul Mezan Chief Biologist
Ms. Guila Assayag Scientist

Portfolio - Current Residents - Nectin


Nectin Therapeutics, established by Integra Holdings in 2017, is dedicated to the development of next generation immuno-oncology antibodies. The company's antibodies are based on the discoveries and inventions of Prof. Ofer Mandelboim from the Hebrew University and Prof. Stipan Jonjic from the University of Rijeka. Integra Holdings & Yissum are the key shareholders.


Dr. Guy Cinamon VP R&D
Dr. Pini Tsukerman CSO
Mr. Anas Atieh Lab manager
Dr. Akram Obiedat Senior Scientist 

Portfolio - Current Residents - Bio-Fence

Bio-fence logo

Bio-Fence is developing a novel anti-microbial organic polymer that can be incorporated into a variety of commercial coatings found in food sites, providing them with the features of a biocide. Originally developed by LSRI (Life Science Research Israel) to protect armed vehicles against anthrax, the company's highly reactive polymer can eliminate up to 99.999% of hazardous pathogens on these surfaces, dramatically reducing their risk of toxicity. It is safe, highly active, low cost, stable, and can be regenerated easily.


Mr. Ofer Shoham  CEO
Dr. Maria Hitrik  CTO
Mr. Raveh Gill-More COO
Dr. Sanaa Halil Senior Chemist
Dr. Pinchas Zeraviv Synthesis Specialist
Ms. Adva Bar-On Coating Specialist

Portfolio - Current Residents - Genetika+

Genetika+ logo

Genetika+ specializes in personalized treatment for individuals suffering from depression. The company is developing the first cellular and genetic-based platform to provide meaningful predictions of patient responses to anti-depressants, in order to identify each person's optimal treatment regimen more rapidly and accurately.



Dr. Talia Cohen Solal CEO
Dr. Daphna Laifenfeld CSO
Dr. Erez Nitzan  VP R&D
Dr. Yishai Avior Senior Scientist
Dr. Sari Natan Senior Scientist
Dr. Rom Altstock Data Scientist 
Ms. Dana Kroitorou Research Associate
Ms. Claudia Albeldas Research associate
Ms. Lena Kreines Student Researcher
Ms. Marva Lachish Student Researcher

Portfolio - Current Residents - Omnix medical


Omnix Medical founded in 2015, is developing novel antibiotic agents for the treatment of hospital-acquired infections involving drug resistant bacteria. Omnix’s technology is based on natural antimicrobial peptides, biochemically engineered to be compatible for therapeutic applications. Omnix’s lead molecule, OMN6, employs a unique mechanism of action, representing a new antibiotic class, characterized by a rapid-bactericidal effect. OMN6 was found to be active irrespective of resistance to other antibiotic drugs, and thus, offers a safer more efficient alternative to current therapies.


Dr. Moshik Cohen-Kutner  Co-Founder & CEO
Dr. Niv Bachnoff  Co-Founder & CSO
Mr. Rom Lakritz  CPA, Co-Founder & CFO/COO
Ms. Shira Merchavia  Research Director
Ms. Janna Michaeli  Preclinical Director  
Dr. Jonathan Zazun  PharmD, CMC Director 
Ms. Noa Nur Research Scientist
Ms. Esti Rotshtein Operations Manage

Portfolio - Current Residents - EggXYt


eggXYt’s mission is to enable a sustainable future in the livestock industry. The company’s technology non-invasively detects the gender of chick embryos immediately after the eggs are laid. Pre-incubation sex detection prevents seven billion male chicks from being unnecessarily hatched and disposed of each year. It saves the industry billions of dollars on unnecessary incubation, human labor for sex detection, and costs of feed in the broiler industry, and adds more than seven billion non-incubated eggs to the global supply.


Professor Daniel Offen  Co-Founder & CSO
Mr. Yehuda Elram  Co Founder & CEO
Dr. Malkiel Cohen Head of Research
Mr. Gal Lin Director of Business Development
Ms. Yirat Henshke Research Assistant
Ms. Limor Panet Research Assistant


Portfolio - Current Residents - Daika

Founded in 2020 and Backed by Terra Lab Ventures, Daika has developed a new material which is 100% wood. The material is based on natural binders and wood particles, and already showed initial POC in industrial molding and extrusion. The resulting products retain the unique properties of wood such as warmth, sense and acoustics and can be processed as regular wood. The material is composed of recycled wood particles and we have demonstrated some products using agriculture waste. We have targeted consumer products and packaging as our first markets.


Dr. Michael Layani CEO and Founder
Prof. Shlomo Magdassi Co-founder
Prof. Oded Shoseyov Co-founder
Mr. Ariel Zinger Lead Scientist
Mr. Elchanan Achituv Chemistry engineer

Portfolio - Current Residents - Pyxis Diagnostics

Pyxis Diagnostics develops a unique platform to identify predictive biomarkers in the field of immuno-oncology. Biological data collected from fresh tumor samples using cell-sorting and NGS enables deep characterization of different cancer, immune and stromal cell populations. This profound analysis allows to delineate the Cellular Suppressive Network (CSN) formed within the tumor microenvironment. Machine learning algorithms are then used for biomarker identification based on differential CSN patterns between responders and non-responders for a given immunotherapy. Pyxis aims to improve outcome for patients and increase success rate of immunotherapies both in clinics and during drug development process.


Dr. Reut Yosef CTO
Dr. Aviv De-Morgan Senior Computational Biologist
Dr. Bar Nathansohn-Levi Senior Scientist
Ms. Ella Niv Scientist


Portfolio - Current Residents - SMT Labs

SMT Labs 

Mosquitoes are the most dangerous animal on earth.
Mosquito-borne diseases like dengue, Zika and malaria infect hundreds of millions every year. Global warming is driving these mosquitoes to spread rapidly, endangering many more.  
SMT Labs’ technology cuts the cost of SIT - a natural and highly efficient insect birth control method - to make it a widespread solution against mosquitoes. 


Mr. Victor Levitin, CEO
Dr. Elly Ordan, CSO
Dr. Ariel Livne, CTO